본문

  1. Home
1000 Results:PP:ELSEVIER PP:ELSEVIER INC 0.281 sec.
RSS 
다국어입력
 상세검색
 신착검색
선택출력 선택엑셀내보내기
41
Pharmacological therapy of Paget's and other metabolic bone diseases
Pharmacological therapy of Paget's and other metabolic bone diseases
Hosking, D., | Elsevier Inc | 2006 ,
42
Protelos: Nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis
Protelos: Nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis
Adami, S, | Elsevier Inc | 2006 ,
43
Strontium ranelate: An increased bone quality leading to vertebral antifracture efficacy at all stages
Strontium ranelate: An increased bone quality leading to vertebral antifracture efficacy at all stages
Ortolani, S., | Elsevier Inc | 2006 ,
44
Strontium ranelate: A physiological approach for an improved bone quality
Strontium ranelate: A physiological approach for an improved bone quality
Ammann, P, | Elsevier Inc | 2006 ,
45
Strontium ranelate: A physiological approach for optimizing bone formation and resorption
Strontium ranelate: A physiological approach for optimizing bone formation and resorption
Marie, P. J., | Elsevier Inc | 2006 ,
46
Osteoporosis: A still increasing prevalence
Osteoporosis: A still increasing prevalence
Reginster, J. Y., | Elsevier Inc | 2006 ,
47
Bone supplement: Proceedings of ECTS/IBMS Geneva 2005–06–20
Bone supplement: Proceedings of ECTS/IBMS Geneva 2005–06–20
Cooper, C., | Elsevier Inc | 2006 ,
48
Fighting osteoporosis on two fronts
Fighting osteoporosis on two fronts
Burckhardt, P., | Elsevier Inc | 2006 ,
49
Sex hormone deprivation and bone merabolism in cancer patients
Sex hormone deprivation and bone merabolism in cancer patients
Maria yavropoulou, | Elsevier Inc | 2011 ,
50
Late-phase clinical date to support the clinical relecance of RANKL inhibition
Late-phase clinical date to support the clinical relecance of RANKL inhibition
Silcano Adami, | Elsevier Inc | 2011 ,
처음이전12345678910이후마지막